Skip to main content

Advertisement

SpringerLink
Log in

Körperstereotaktische Bestrahlung als „Erstlinientherapie“ des oligometastasierten Nierenzellkarzinoms

Stereotactic body radiotherapy as “first-line treatment” for oligometastatic renal cell cancer

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Siva S et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK): pooled analysis of SABR for primary RCC. Cancer 124:934–942

    Article  Google Scholar 

  2. Hoerner-Rieber J et al (2017) Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma‑a multicenter analysis of the German working group “Stereotactic Radiotherapy”. J Thorac Dis 9:4512–4522

    Article  Google Scholar 

  3. Kroeze SGC et al (2021) Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int 127:703–711

    Article  CAS  Google Scholar 

  4. Sheehan JP, Sun M‑H, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342–349

    Article  Google Scholar 

  5. Palma DA et al (2019) Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.6993

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chang JY et al (2021) Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22:1448–1457

    Article  Google Scholar 

  7. Aeppli S et al (2021) First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open 6(1):100030

    Article  CAS  Google Scholar 

  8. Motzer RJ et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290

    Article  CAS  Google Scholar 

  9. Rini BI et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1816714

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang Y et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol 105:367–375

    Article  CAS  Google Scholar 

  11. Rini BI et al (2016) Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 17:1317–1324

    Article  Google Scholar 

  12. Harrison MR et al (2021) Active surveillance of metastatic renal cell carcinoma: results from a prospective observational study (MaRCC). Cancer 127:2204–2212

    Article  Google Scholar 

  13. Corradini S et al (2019) MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol 14:92

    Article  CAS  Google Scholar 

  14. Siva S et al (2021) Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma—the RAPPORT trial. Eur Urol. https://doi.org/10.1016/j.eururo.2021.12.006

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Universitäts-Spital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz

    Matthias Guckenberger MD

Authors
  1. Matthias Guckenberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Guckenberger MD.

Ethics declarations

Interessenkonflikt

M. Guckenberger gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Tang C et al (2021) Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility phase 2 trial. Lancet Oncol 22(12):1732–1739. https://doi.org/10.1016/S1470-2045(21)00528-3

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guckenberger, M. Körperstereotaktische Bestrahlung als „Erstlinientherapie“ des oligometastasierten Nierenzellkarzinoms. Strahlenther Onkol 198, 497–499 (2022). https://doi.org/10.1007/s00066-022-01920-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-01920-7

Search

Navigation